AstraZeneca shares jump after J.P. Morgan reiterates Overweight
AZN rose about 2.16% intraday after J.P. Morgan reiterated an Overweight rating, citing six Phase III readouts due in 2027 with more than $10 billion in risk-adjusted peak sales.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.